Misoprostol
- Generic Name
- Misoprostol
- Brand Names
- Arthrotec, Cytotec, Mifegymiso
- Drug Type
- Small Molecule
- Chemical Formula
- C22H38O5
- CAS Number
- 59122-46-2
- Unique Ingredient Identifier
- 0E43V0BB57
- Background
Misoprostol is a prostaglandin analog used to reduce the risk of NSAID related ulcers, manage miscarriages, prevent post partum hemorrhage, and also for first trimester abortions. The stimulation of prostaglandin receptors in the stomach reduces gastric acid secretion, while stimulating these receptors in the uterus and cervix can increase the strength and frequency of contractions and decrease cervical tone.
Misoprostol was granted FDA approval on 27 December 1988.
- Indication
Misoprostol is indicated as a tablet to reduce the risk of NSAID induced gastric ulcers but not duodenal ulcers in high risk patients. Misoprostol is also formulated in combination with diclofenac to treat symptoms of osteoarthritis or rheumatoid arthritis in patients with a high risk of developing gastric ulcers. Misoprostol is used off label for the management of miscarriages, prevention of post partum hemorrhage, and is also used alone or in combination with mifepristone in other countries for first trimester abortions.
- Associated Conditions
- Gastric Ulcer, Incomplete Abortion, Missed Abortion, Postpartum Haemorrhage (PPH)
- Associated Therapies
- Induction of cervix ripening therapy, Medically induced abortion
Comparison of the Efficacy of Misoprostol and Tranexamic Acid for Postpartum Hemorrhage Prophylaxis in Cesarean Delivery
- Conditions
- Cesarean Section ComplicationsDelivery ComplicationPostpartum Hemorrhage
- Interventions
- First Posted Date
- 2025-05-14
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Ankara Etlik City Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT06970483
- Locations
- 🇹🇷
Etlik City Hospital, Ankara, Turkey
Misoprostol Before Caesarean Section
- Conditions
- MisoprostolRespiratory Distress Syndrome (RDS) of NeonateCaesarean Section
- Interventions
- First Posted Date
- 2025-04-27
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Kafrelsheikh University
- Target Recruit Count
- 160
- Registration Number
- NCT06946914
- Locations
- 🇪🇬
Kafr El-sheikh University Hospital, Kafr Ash Shaykh, Egypt, Egypt
Misoprostol Versus Dinoprostone in Induction of Labor
- First Posted Date
- 2025-04-03
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Al-Azhar University
- Target Recruit Count
- 200
- Registration Number
- NCT06909721
- Locations
- 🇪🇬
Al-Azhar University Hospitals, Assiut, Assuit, Egypt
Comparison Between Vaginal Misoprostol Gel and Oral Misoprostol Solution in Induction of Labor
- Conditions
- Cervical Ripening and Induction of Labor
- Interventions
- Drug: Oral misoprostol solution (OMS)
- First Posted Date
- 2025-03-13
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Hagar Muhammad Abdulfattah Muhammad
- Target Recruit Count
- 80
- Registration Number
- NCT06874049
- Locations
- 🇪🇬
Ain Shams university Maternity Hospital, Cairo, Egypt
Foley Balloon for Cervical Preparation Before Dilation and Evacuation
- Conditions
- Abortion, Second TrimesterAbortion, Medical
- Interventions
- First Posted Date
- 2025-02-28
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Stony Brook University
- Target Recruit Count
- 102
- Registration Number
- NCT06850974
- Locations
- 🇲🇿
Hospital Central De Maputo, Maputo, Mozambique
Comparison Between Preoperative Vaginal and Postoperative Sublingual Misoprostol for Prevention of Postpartum Hemorrhage During Cesarean Section
- First Posted Date
- 2025-01-09
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 400
- Registration Number
- NCT06765473
Significance of Misoprostol-induced Cervical Ripening Prior to Hysteroscopy
- Conditions
- HysteroscopyCervical Ripening
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Hayat Abad Medical Complex, Peshawar.
- Target Recruit Count
- 539
- Registration Number
- NCT06726278
- Locations
- 🇵🇰
Hayatabad Medical Complex, Peshawar, Khyber Pukhtoonkhwa, Pakistan
Use Misoprostol to Optimize Prevention of Cervical Cancer
- First Posted Date
- 2024-11-01
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 420
- Registration Number
- NCT06669533
- Locations
- 🇨🇲
Cameroon Baptist Convention Health Core, EtougEbe Baptist Hospital Yaoundé, Yaoundé, Center Region, Cameroon
Mifepristone vs Misoprostol
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 94
- Registration Number
- NCT06502158
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
Letrozole and Misoprostol for Early Pregnancy Loss Management
- Conditions
- Miscarriage in First TrimesterEarly Pregnancy LossMiscarriage
- Interventions
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 30
- Registration Number
- NCT06452719
- Locations
- 🇺🇸
PEACE / Penn Medicine, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.